Epstein-Barr virus replicating in epithelial cells, Proc Natl Acad Sci U S A, vol.111, p.25385596, 2014. ,
Epstein-Barr virus: 40 years on, Nat Rev Cancer, vol.4, p.15510157, 2004. ,
Epstein-Barr virus in systemic autoimmune diseases, Clin Dev Immunol, p.24062777, 2013. ,
The EB virus, Annu Rev Microbiol, vol.27, p.4356531, 1973. ,
Epstein-barr virus vaccines, Clin Transl Immunology, vol.4, p.25671130, 2015. ,
Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults, J Infect Dis, vol.196, p.18190254, 2007. ,
Translational profiling of B cells infected with the Epstein-Barr virus reveals 5' leader ribosome recruitment through upstream open reading frames, Nucleic Acids Res, vol.46, p.29529302, 2018. ,
Reevaluation of human cytomegalovirus coding potential, Proc Natl Acad Sci U S A, vol.100, p.14593199, 2003. ,
KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features, PLoS Pathog, vol.10, p.24453964, 2014. ,
The immunology of Epstein-Barr virus-induced disease, Annu Rev Immunol, vol.33, p.25706097, 2015. ,
First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen, Dev Biol Stand, vol.84, p.7796951, 1995. ,
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site, Cell, vol.162, p.26279189, 2015. ,
Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis, J Virol, vol.82, p.18032491, 2008. ,
An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA, J Virol, vol.87, p.23236073, 2013. ,
Proteins of purified Epstein-Barr virus, Proc Natl Acad Sci U S A, vol.101, p.15534216, 2004. ,
CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines, J Virol, vol.79, p.15795275, 2005. ,
Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy, PLoS One, vol.2, p.17611619, 2007. ,
Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4+ T cells, Blood, vol.125, p.25568348, 2015. ,
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen, Proc Natl Acad Sci, vol.77, p.6248876, 1980. ,
Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response, J Virol, vol.83, p.19244320, 2009. ,
Epstein-Barr virus particles induce centrosome amplification and chromosomal instability, Nat Commun, vol.8, p.28186092, 2017. ,
Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay, Immunology, vol.139, p.23560877, 2013. ,
Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles, J Virol, vol.82, p.18272580, 2008. ,
Virus and autoantigenspecific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders, PLoS Pathog, vol.10, p.24853673, 2014. ,
Virus-specific CD4+ T cells: ready for direct attack, J Exp Med, vol.203, p.16549599, 2006. ,
The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection, Eur J Cell Biol, vol.91, p.21458882, 2012. ,
Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo, Leukemia, 2018. ,
Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection, Proc Natl Acad Sci U S A, vol.99, p.12409611, 2002. ,
Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas, Cell Rep, vol.5, p.24120866, 2013. ,
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses, Blood, vol.112, p.18519810, 2008. ,
CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation, J Virol, vol.75, p.11264363, 2001. ,
New flow cytometric assays for monitoring cell-mediated cytotoxicity, Expert Rev Vaccines, vol.9, p.20518716, 2010. ,
Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1, J Exp Med, vol.191, p.10811859, 2000. ,
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function, J Clin Invest, vol.107, p.11134187, 2001. ,
Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins, J Exp Med, vol.203, p.16549597, 2006. ,
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components, J Exp Med, vol.206, p.19487422, 2009. ,
Human immunity against EBV-lessons from the clinic, vol.214, p.28108590, 2017. ,
CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells, J Exp Med, vol.201, p.15684323, 2005. ,
CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response, J Immunol, vol.191, p.24146041, 2013. ,
Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination, PLoS Pathog, vol.12, p.27096949, 2016. ,
Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection, PLOS Pathogens, vol.14, p.30248160, 2018. ,
Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine, Nature, vol.318, p.2999604, 1985. ,
A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice, J Transl Med, vol.13, p.25885535, 2015. ,
Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo, J Virol, vol.43, p.6287039, 1982. ,
Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells, Proc Natl Acad Sci U S A, vol.103, p.16606841, 2006. ,
Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry, Nature Microbiology, vol.3, pp.164-171, 2018. ,
Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus, Nature Microbiology, vol.3, p.29292384, 2018. ,
An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus, Immunity, vol.48, p.29669253, 2018. ,
Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBVspecific antibody-dependent cellular cytotoxicity, J Virol, vol.65, p.1846213, 1991. ,
Human antibody titers to EpsteinBarr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay, Virology, vol.391, p.19584018, 2009. ,
How I treat EBV lymphoproliferation, Blood, vol.114, pp.4002-4008, 2009. ,
Persistence of the Epstein-Barr virus and the origins of associated lymphomas, N Engl J Med, vol.350, p.15044644, 2004. ,
Adoptive T-Cell Immunotherapy, Curr Top Microbiol Immunol, vol.391, p.26428384, 2015. ,
Immunotherapy for EBV-associated malignancies, Int J Hematol, vol.93, p.21336546, 2011. ,
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients, Blood, vol.92, p.9716582, 1998. ,
A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses, J Infect Dis, vol.198, p.18627269, 2008. ,
Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Types, Curr Top Microbiol Immunol, vol.390, p.26424646, 2015. ,
Epstein-Barr virus strain heterogeneity impairs human T-cell immunity, Cancer Immunology, Immunotherapy, vol.67, p.29374782, 2018. ,
, AFRICAN LYMPHOMA). Lancet, vol.1, p.14086209, 1964.
Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J Gen Virol, vol.36, p.886304, 1977. ,
Simple and highly efficient BAC recombineering using galK selection, Nucleic Acids Res, vol.33, p.15731329, 2005. ,
Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells, Proc Natl Acad Sci U S A, vol.95, p.9653172, 1998. ,
Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands, J Virol, vol.74, p.11024143, 2000. ,
The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple Functions in Primary B Cells, PLoS Pathog, vol.11, p.26694854, 2015. ,